Annual report
6523.TEDINET S100TU2J
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 151
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥353.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥356.4bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥306.1bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥272.6bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥20.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥179m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥5.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥16.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥5.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥564.3bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥561.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥569.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥529.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥425.2bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥422.7bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥139.5bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥138.0bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥107.0bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥70.3bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥47.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥45.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥41.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥47.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥36.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥17.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥16.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥135.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥39.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥20.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥95.6bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥149.07 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥46.61 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥143.93 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥45.22 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,106.98 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,101.33 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,092.33 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥921.04 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥619.38 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 24.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.6% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 13.3% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | -9.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -2.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -7.0% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,245 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 9,403 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 9,374 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 9,753 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 9,615 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥39.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥32.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥39.2bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥8.8bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.8bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥30.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥20.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥23.3bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥21.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥9.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥11.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥17.7bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥16.4bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥19.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥19.9bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥132m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥10.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥467.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥457.3bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥467.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥432.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥408.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥372.3bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥360.6bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥94.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥96.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥96.8bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥50.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥40.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥11.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥22.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥130.25 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.96 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.62 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.17 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-92.71 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥129.59 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥153.15 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.08 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥54 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥751.98 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥759.31 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥763.79 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥355.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 20.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 9.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 17.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 20.4% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 126,244,271 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,522,074 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 124,144,242 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 114,831,084 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,973,941 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 141 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 151 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 175 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 181 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 186 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 325 pure |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | ¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥10.6bn |
| Diabetes Managementreportable segment | employees | at 2024-03-31 | 2807 pure |
| Diabetes Managementreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥109.1bn |
| Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥109.1bn |
| Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥15.3bn |
| Diagnostics And Life Sciencesreportable segment | employees | at 2024-03-31 | 2274 pure |
| Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥109.0bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥109.0bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥6.0bn |
| Healthcare Solutionsreportable segment | employees | at 2024-03-31 | 3839 pure |
| Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥133.4bn |
| Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥133.4bn |
| Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥9.2bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥351.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥12.2bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥15.5bn |
| Diabetes Managementreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥111.8bn |
| Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥111.8bn |
| Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥26.7bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥108.8bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥108.8bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥133.6bn |
| Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥133.6bn |
| Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥9.8bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥354.2bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥354.2bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥35.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 141 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,010
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes refund ope cf IFRS | CurrentYearDuration | 6694000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YearDuration | 21376000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYearDuration | 41304000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | Prior1YearDuration | -11516000000 | JPY |
| Purchase of property plant and equipment and intangible assets inv cf IFRS | CurrentYearDuration | -14630000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | Prior1YearDuration | 297000000 | JPY |
| Proceeds from sale of property plant and equipment and intangible assets inv cf IFRS | CurrentYearDuration | 351000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YearDuration | -1797000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYearDuration | -11500000000 | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | Prior1YearDuration | -441000000 | JPY |
| Purchase of investments accounted for using equity method inv cf IFRS | CurrentYearDuration | -351000000 | JPY |
| Proceeds from sale of investments accounted for using equity method inv cf IFRS | Prior1YearDuration | － | JPY |
| Proceeds from sale of investments accounted for using equity method inv cf IFRS | CurrentYearDuration | 3821000000 | JPY |
| Purchase of investments inv cf IFRS | Prior1YearDuration | -3064000000 | JPY |
| Purchase of investments inv cf IFRS | CurrentYearDuration | － | JPY |
| Other inv cf IFRS | Prior1YearDuration | -998000000 | JPY |
| Other inv cf IFRS | CurrentYearDuration | 1236000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YearDuration | -17520000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYearDuration | -21072000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YearDuration | -265000000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYearDuration | 5000000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YearDuration | － | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYearDuration | 62215000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YearDuration | -25931000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYearDuration | -88241000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YearDuration | -5749000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYearDuration | -6180000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | Prior1YearDuration | 450000000 | JPY |
| Proceeds from issuance of shares fin cf IFRS | CurrentYearDuration | 231000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YearDuration | － | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYearDuration | -2611000000 | JPY |
| Dividends paid to owners of parent fin cf IFRS | Prior1YearDuration | -9196000000 | JPY |
| Dividends paid to owners of parent fin cf IFRS | CurrentYearDuration | -9040000000 | JPY |
| Other fin cf IFRS | Prior1YearDuration | -139000000 | JPY |
| Other fin cf IFRS | CurrentYearDuration | -511000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YearDuration | -40832000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYearDuration | -39139000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YearDuration | 2676000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYearDuration | 5017000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YearDuration | -34298000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYearDuration | -13889000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 95232000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 60933000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 60933000000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 47044000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E36976-000DiabetesManagementReportableSegmentMember | 111826000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E36976-000HealthcareSolutionsReportableSegmentMember | 133550000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 108774000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReportableSegmentsMember | 354151000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReconcilingItemsMember | 2283000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |